Utility DONG Energy and biogas plant builder Bigadan have said they will fund the construction of an innovative facility using anaerobic digestion to process leftovers from insulin and enzyme production.
The plant, which was first revealed in September 2015, will have a production capacity of 8 million m2 of biogas per year. Originally, the two had indicated a capacity of about 6 million.
While no financial terms were disclosed, DONG says it plans to move to construction this month, with the facility due to be operational in early 2018
The plant would be built in Kalundborg, Zealand, where both Novo Nordisk and Novozymes have facilities producing enzymes and insulin for global distribution.
By-product of the production, which is currently used as a fertiliser and by Novo Nordisk to produce biogas at smaller installations around Zealand, will be the plant’s main feedstock.
Feedstock will be sourced from Novo Nordisk and Novozymes factories in Kalundborg and from their facilities in Fuglebakken, Copenhagen.
The biogas facility itself, will be located near the Asnæs power station, which DONG also owns to the south of Kalundborg, and is currently converting to biomass.
Read more here.